A Study of Olaratumab (IMC-3G3) in Prostate Cancer

NCT01204710 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: Olaratumab
DRUG: Mitoxantrone
DRUG: Prednisone

Sponsor

Eli Lilly and Company